Introduction to CCDC116, A Potential Drug Target (G164592)

Target Name: CCDC116

NCBI ID: G164592

CCDC116

Introduction to CCDC116, A Potential Drug Target
CCDC116, also known as Coiled-Coil Domain Containing 116, is a protein that has emerged as a potential drug target and biomarker for various diseases. This article will explore the unique features of CCDC116 and its implications in the field of medicine.

Understanding CCDC116
CCDC116 is a protein encoded by the CCDC116 gene located on human chromosome 19. It belongs to a class of proteins characterized by a coiled-coil domain, which facilitates protein-protein interactions and can play a vital role in cellular processes. CCDC116 is predominantly expressed in certain tissues, such as the testes, brain, and liver.

CCDC116 as a Potential Drug Target
One significant aspect of CCDC116 is its involvement in multiple pathological conditions. Researchers have identified its role in cancer, where aberrant expression of CCDC116 has been observed in several tumor types. For example, studies have shown that CCDC116 is overexpressed in lung cancer cells and contributes to tumor growth and metastasis. Targeting CCDC116 in cancer therapy holds promise as a potential strategy to inhibit tumor progression.

Furthermore, CCDC116 has been implicated in neurological disorders. In Alzheimer's disease, the protein is upregulated in affected brain regions, suggesting its potential contribution to the disease pathology. By understanding the molecular mechanisms underlying CCDC116's involvement in these diseases, scientists can develop targeted therapies to modulate its activity and potentially mitigate disease progression.

CCDC116 as a Biomarker
Biomarkers play a crucial role in disease diagnosis, prognosis, and treatment monitoring. CCDC116 has shown promise as a biomarker due to its tissue-specific expression and altered levels in various diseases. In lung cancer, for example, CCDC116 expression levels have been correlated with tumor stage and prognosis. High expression levels of CCDC116 were associated with more aggressive tumor behavior and a poorer overall survival rate.

The use of CCDC116 as a biomarker extends beyond cancer. In other diseases, such as neurodegenerative disorders, monitoring CCDC116 levels in cerebrospinal fluid or blood samples may aid in disease diagnosis and progression tracking. As ongoing research continues to shed light on CCDC116's involvement in different disease processes, its potential as a biomarker will become increasingly significant.

Potential Therapeutic Approaches
The identification of CCDC116 as a potential drug target opens up avenues for therapeutic interventions. One approach is to develop small molecule inhibitors that selectively target CCDC116, either by interfering with its protein-protein interactions or modulating its downstream signaling pathways. Such inhibitors could reduce the oncogenic activity of CCDC116 and alleviate disease symptoms.

Another therapeutic strategy is to employ gene therapy techniques. By targeting the CCDC116 gene, it is possible to downregulate its expression or modify its activity through RNA interference or gene-editing technologies. This approach holds promise, particularly in diseases where CCDC116 plays a causative role, such as certain cancers and neurological disorders.

Conclusion
CCDC116, a coiled-coil domain-containing protein, shows great promise as both a drug target and biomarker. Its tissue-specific expression and involvement in various diseases make it an attractive candidate for therapeutic interventions. As researchers continue to unravel the molecular mechanisms underlying its functions, new opportunities may arise for developing precise and targeted therapeutic strategies. Additionally, the ability to use CCDC116 as a biomarker could enhance disease diagnosis and prognosis, enabling personalized treatment plans for patients. The future looks bright for CCDC116, with its potential to contribute significantly to the field of medicine.

Protein Name: Coiled-coil Domain Containing 116

The "CCDC116 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC116 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets